Brief report: Nectin-1 is a marker of thyroid cancer sensitivity to herpes oncolytic therapy

Journal of Clinical Endocrinology and Metabolism

Volumn 92, Issue 5, 2007, Pages 1965-1970

  Huang, Yu Yao ^a,b   Yu, Zhenkun ^a   Lin, Shu Fu ^a,b   Li, Sen ^a   Fong, Yuman ^a   Wong, Richard J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

NECTIN 1; ONCOLYTIC HERPES VIRUS; CELL ADHESION MOLECULE; HEPARIN; HERPESVIRUS ENTRY MEDIATOR; NECTINS; TUMOR MARKER; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

ANAPLASTIC CARCINOMA; ARTICLE; CANCER CELL CULTURE; CANCER SUSCEPTIBILITY; CELL SORTER; CONTROLLED STUDY; CORRELATION COEFFICIENT; CYTOTOXICITY; FLUORESCENCE; FOLLICULAR CARCINOMA; HUMAN; HUMAN CELL; MEDULLARY CARCINOMA; PAPILLARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYROID CANCER; ANIMAL; CHO CELL; CRICETULUS; FLOW CYTOMETRY; GENETIC TRANSFECTION; GENETICS; HAMSTER; HERPES SIMPLEX VIRUS 1; METABOLISM; ONCOLYTIC VIROTHERAPY; THYROID TUMOR; TUMOR CELL LINE;

HERPES; HERPESVIRIDAE; SIMPLEXVIRUS;

ANIMALS; CELL ADHESION MOLECULES; CELL LINE, TUMOR; CHO CELLS; CRICETINAE; CRICETULUS; FLOW CYTOMETRY; HEPARIN; HERPESVIRUS 1, HUMAN; HUMANS; ONCOLYTIC VIROTHERAPY; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 14; THYROID NEOPLASMS; TRANSFECTION; TUMOR MARKERS, BIOLOGICAL; VIRAL ENVELOPE PROTEINS;

EID: 34249847038     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2007-0040     Document Type: Article

References (20)

1. Sherman SI 2003 Thyroid carcinoma. Lancet 361:501-511
2. Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM 1991 Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252:854-856
3. Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL 1995 Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1:938-943
4. Walker JR, McGeagh KG, Sundaresan P, Jorgensen TJ, Rabkin SD, Martuza RL 1999 Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207. Hum Gene Ther 10:2237-2243
5. Coukos G, Makrigiannakis A, Kang EH, Rubin SC, Albelda SM, Molnar-Kimber KL 2000 Oncolytic herpes simplex virus-1 lacking ICP34.5 induces p53-independent death and is efficacious against chemotherapy-resistant ovarian cancer. Clin Cancer Res 6:3342-3353
6. Kooby DA, Carew JF, Halterman MW, Mack JE, Bertino JR, Blumgart LH, Federoff HJ, Fong Y 1999 Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207). FASEB J 13:1325-1334
7. Wong RJ, Kim SH, Joe JK, Shah JP, Johnson PA, Fong Y 2001 Effective treatment of head and neck squamous cell carcinoma by an oncolytic herpes simplex virus. J Am Coll Surg 193:12-21
8. Markert JM, Medlock MD, Rabkin SD, Gillespie GY, Todo T, Hunter WD, Palmer CA, Feigenbaum F, Tornatore C, Tufaro F, Martuza RL 2000 Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 7:867-874
9. Rampling R, Cruickshank G, Papanastassiou V, Nicoll J, Hadley D, Brennan D, Petty R, MacLean A, Harland J, McKie E, Mabbs R, Brown M 2000 Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther 7:859-866
10. Kemeny N, Brown K, Covey A, Kim T, Bhargava A, Brody L, Guilfoyle B, Haag NP, Karrasch M, Glasschroeder B, Knoll A, Getrajdman G, Kowal KJ, Jarnagin WR, Fong Y 2006 Phase 1, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver. Hum Gene Ther 17:1214-1224
11. Wong RJ, Patel SG, Kim S, DeMatteo RP, Malhotra S, Bennett JJ, St. Louis M, Shah JP, Johnson PA, Fong Y 2001 Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma. Hum Gene Ther 12:253-265
12. Wong RJ, Joe JK, Kim SH, Shah JP, Horsburgh B, Fong Y 2002 Oncolytic herpesvirus effectively treats murine squamous cell carcinoma and spreads by natural lymphatics to treat sites of lymphatic metastases. Hum Gene Ther 13:1213-1223
13. Wong RJ, Chan MK, Yu Z, Kim TH, Bhargava A, Stiles BM, Horsburgh BC, Shah JP, Ghossein RA, Singh B, Fong Y 2004 Effective intravenous therapy of murine pulmonary metastases with an oncolytic herpes virus expressing interleukin 12. Clin Cancer Res 10:251-259
14. Yu Z, Eisenberg DP, Singh B, Shah JP, Fong F, Wong RJ 2004 Treatment of aggressive thyroid cancer with an oncolytic herpes virus. Int J Cancer 112:525-532
15. Spear PG, Longnecker R 2003 Herpesvirus entry: an update. J Virol 77:10179-10185
16. Krummenacher C, Baribaud F, Ponce de Leon M, Baribaud I, Whitbeck JC, Xu R, Cohen GH, Eisenberg RJ 2004 Comparative usage of herpesvirus entry mediator A and nectin-1 by laboratory strains and clinical isolates of herpes simplex virus. Virology 322:286-299
17. Bennett JJ, Delman KA, Burt BM, Mariotti A, Malhotra S, Zager J, Petrowsky H, Mastorides S, Federoff H, Fong Y 2002 Comparison of safety, delivery, and efficacy of two oncolytic herpes viruses (G207 and NV1020). Cancer Gene Ther 9:935-945
18. McAuliffe PF, Jarnagin WR, Johnson P, Delman KA, Federoff H, Fong Y 2000 Effective treatment of pancreatic tumors with two multimutated herpes simplex oncolytic viruses. J Gastrointest Surg 6:580-588
19. Yu Z, Adusumilli PS, Eisenberg DP, Darr E, Ghossein RA, Li S, Liu S, Singh B, Shah JP, Fong Y, Wong RJ 2007 Nectin-1 expression by squamous cell carcinoma is a predictor of herpes oncolytic sensitivity. Mol Ther 15:103-113
20. Farassati F, Yang AD, Lee PW 2001 Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1. Nat Cell Biol 3:745-750